Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of[...]
Regeneron Pharmaceuticals Inc.
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of[...]
Title and Summary Summary ToggleSynaptics Incorporated Prices $400.0[...]
14/11/2024 | Press release | Distributed by Public on 14/11/2024 19:26
Please select the service you want to use:
Smartlinks | Netfonds AG | News | Crime and Judiciary | Crime | Corporate Crime | Finance | Stock Markets | Security Markets | Fixed Income | Bonds | Stock Markets | Security Markets | Company News | Issue of Shares and Capital Increase | Corporate Debt | Corporate Bonds | Financial Services | Investment Services | Securities Issuers | Investment Service Companies | Frankfurt Stock Exchange | Berlin Stock Exchange | Dusseldorf Stock Exchange | Hamburg Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | Tradegate Exchange | XETRA | Cboe Off Exchange
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact